Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311–21.
Article
PubMed
Google Scholar
Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998;3(1):49–61.
Article
PubMed
CAS
Google Scholar
Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001;11(5):339–52.
Article
PubMed
CAS
Google Scholar
Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem. 2002;277(25):22558–65.
Article
PubMed
CAS
Google Scholar
Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle. 2007;6(16):2010–8.
Article
PubMed
CAS
Google Scholar
Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer. 2014;14(1):26–38.
Article
PubMed
CAS
Google Scholar
Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451–86.
Article
PubMed
CAS
Google Scholar
Dey P, Barros RP, Warner M, Strom A, Gustafsson JA. Insight into the mechanisms of action of estrogen receptor beta in the breast, prostate, colon, and CNS. J Mol Endocrinol. 2013;51(3):T61–74.
Article
PubMed
CAS
Google Scholar
Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol. 1999;13(10):1672–85.
Article
PubMed
CAS
Google Scholar
Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122(1):33–43.
Article
PubMed
CAS
Google Scholar
Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson JA, et al. Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res. 2010;70(12):5174–83.
Article
PubMed
CAS
Google Scholar
Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D, et al. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001;60(3):595–602.
PubMed
CAS
Google Scholar
Sun PM, Gao M, Wei LH, Mustea A, Wang JL, Konsgen D, et al. An estrogen receptor alpha-dependent regulation of estrogen receptor-related receptor alpha in the proliferation of endometrial carcinoma cells. Int J Gynecol Cancer. 2006;16(Suppl 2):564–8.
Article
PubMed
Google Scholar
Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64(1):423–8.
Article
PubMed
CAS
Google Scholar
Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A. 2004;101(6):1566–71.
Article
PubMed
PubMed Central
CAS
Google Scholar
Stanford JL, Szklo M, Brinton LA. Estrogen receptors and breast cancer. Epidemiol Rev. 1986;8:42–59.
Article
PubMed
CAS
Google Scholar
Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res. 2015;17:40.
Article
PubMed
PubMed Central
CAS
Google Scholar
Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006;12(16):4790–3.
Article
PubMed
CAS
Google Scholar
Luzhna L, Lykkesfeldt AE, Kovalchuk O. Altered radiation responses of breast cancer cells resistant to hormonal therapy. Oncotarget. 2015;6(3):1678–94.
Article
PubMed
Google Scholar
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.
Article
PubMed
PubMed Central
CAS
Google Scholar
Nicholson RI, Johnston SR. Endocrine therapy--current benefits and limitations. Breast Cancer Res Treat. 2005;93(Suppl 1):S3–10.
Article
PubMed
CAS
Google Scholar
Johnston SR, Martin LA, Dowsett M. Life following aromatase inhibitors--where now for endocrine sequencing? Breast Cancer Res Treat. 2005;93(Suppl 1):S19–25.
Article
PubMed
CAS
Google Scholar
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a north American trial. J Clin Oncol. 2002;20(16):3386–95.
Article
PubMed
CAS
Google Scholar
Lykkesfeldt AE, Briand P. Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer. 1986;53(1):29–35.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994;54(6):1587–95.
PubMed
CAS
Google Scholar
Wang B, Chen J, Santiago FS, Janes M, Kavurma MM, Chong BH, et al. Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. Arterioscler Thromb Vasc Biol. 2010;30(3):536–45.
Article
PubMed
CAS
Google Scholar
Wang B, Li D, Sidler C, Rodriguez-Juarez R, Singh N, Heyns M, et al. A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1. Oncotarget. 2015;6(12):9937–50.
PubMed
PubMed Central
Google Scholar
Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.
Article
PubMed
CAS
Google Scholar
Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643–58.
Article
PubMed
CAS
Google Scholar
Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68(3):826–33.
Article
PubMed
CAS
Google Scholar
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 2009;114(2):263–75.
Article
PubMed
CAS
Google Scholar
Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW. Estrogen receptor alpha is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat. 2013;139(1):71–80.
Article
PubMed
CAS
Google Scholar
Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, et al. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol. 2005;93(2–5):257–62.
Article
PubMed
CAS
Google Scholar
Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80(10):2918–25.
PubMed
CAS
Google Scholar
Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer. 2005;12(Suppl 1):S75–84.
Article
PubMed
CAS
Google Scholar
Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278(33):30458–68.
Article
PubMed
CAS
Google Scholar
Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2015;34(15):1919–27.
Article
PubMed
CAS
Google Scholar
Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, et al. A kinase inhibitor screen identifies Mcl-1 and aurora kinase a as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene. 2015;34(32):4199–5210.
Article
PubMed
CAS
Google Scholar
Lin X, Li J, Yin G, Zhao Q, Elias D, Lykkesfeldt AE, et al. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res. 2013;15(6):R119.
Article
PubMed
PubMed Central
CAS
Google Scholar
Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2008;9(1):60–71.
Article
PubMed
CAS
Google Scholar
Block H, Stadtmann A, Riad D, Rossaint J, Sohlbach C, Germena G, et al. Gnb isoforms orchestrate a signaling pathway comprising Rac1 and Plcbeta2/3 leading to LFA-1 activation and neutrophil arrest in vivo. Blood. 2016;127(3):314–24.
Article
PubMed
PubMed Central
CAS
Google Scholar
Soong BW, Huang YH, Tsai PC, Huang CC, Pan HC, Lu YC, et al. Exome sequencing identifies GNB4 mutations as a cause of dominant intermediate Charcot-Marie-tooth disease. Am J Hum Genet. 2013;92(3):422–30.
Article
PubMed
PubMed Central
CAS
Google Scholar
Baets J, De Jonghe P, Timmerman V. Recent advances in Charcot-Marie-tooth disease. Curr Opin Neurol. 2014;27(5):532–40.
Article
PubMed
CAS
Google Scholar
Riemann K, Struwe H, Alakus H, Obermaier B, Schmitz KJ, Schmid KW, et al. Association of GNB4 intron-1 haplotypes with survival in patients with UICC stage III and IV colorectal carcinoma. Anticancer Res. 2009;29(4):1271–4.
PubMed
CAS
Google Scholar
Riemann K, Struwe H, Eisenhardt A, Obermaier B, Schmid KW, Siffert W. Characterization of intron-1 haplotypes of the G protein beta 4 subunit gene--association with survival and progression in patients with urothelial bladder carcinoma. Pharmacogenet Genomics. 2008;18(11):999–1008.
Article
PubMed
CAS
Google Scholar
Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, et al. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics. 2009;8(6):1278–94.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ryoo HD, Bergmann A. The role of apoptosis-induced proliferation for regeneration and cancer. Cold Spring Harb Perspect Biol. 2012;4(8):a008797.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dichtel-Danjoy ML, Ma D, Dourlen P, Chatelain G, Napoletano F, Robin M, et al. Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. Cell Death Differ. 2013;20(1):108–16.
Article
PubMed
CAS
Google Scholar
Mollereau B, Perez-Garijo A, Bergmann A, Miura M, Gerlitz O, Ryoo HD, et al. Compensatory proliferation and apoptosis-induced proliferation: a need for clarification. Cell Death Differ. 2013;20(1):181.
Article
PubMed
CAS
Google Scholar
Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma. J Biol Chem. 1998;273(30):19080–5.
Article
PubMed
CAS
Google Scholar
Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006;66(6):3071–7.
Article
PubMed
CAS
Google Scholar
Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079–93.
Article
PubMed
CAS
Google Scholar
Knoblich JA, Sauer K, Jones L, Richardson H, Saint R, Lehner CF. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell. 1994;77(1):107–20.
Article
PubMed
CAS
Google Scholar
Niehrs C, Acebron SP. Mitotic and mitogenic Wnt signalling. EMBO J. 2012;31(12):2705–13.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ogura Y, Sakaue-Sawano A, Nakagawa M, Satoh N, Miyawaki A, Sasakura Y. Coordination of mitosis and morphogenesis: role of a prolonged G2 phase during chordate neurulation. Development. 2011;138(3):577–87.
Article
PubMed
CAS
Google Scholar
Cheng A, Solomon MJ. Speedy/Ringo C regulates S and G2 phase progression in human cells. Cell Cycle. 2008;7(19):3037–47.
Article
PubMed
PubMed Central
CAS
Google Scholar